Skip to main content
. 2024 Jul 23;3(5):191–199. doi: 10.1016/j.cjcpc.2024.07.002

Figure 1.

Figure 1

Changes in systemic right ventricle ejection fraction. (A) Systemic right ventricle ejection fraction (sRVEF) improved in all patients treated with ACE-I/ARB from 50.7% ± 9.0% at the initial assessment to 57.0% ± 8.6% at the last assessment (N = 17, Wilcoxon matched-pairs signed-rank test, P = 0.0399). The patients were divided into 2 groups based on the severity of tricuspid regurgitation (TR). (B) The mild TR group showed a significant improvement in sRVEF from 49.1% ± 8.4% to 56.7% ± 8.0% (N = 12, Wilcoxon matched-pairs signed-rank test, P = 0.0029), whereas (C) there was no sRVEF improvement in the moderate or severe TR group (from 54.6% ± 10.0% to 57.7% ± 10.9%; N = 5, Wilcoxon matched-pairs signed-rank test, P > 0.9999). ACE-I/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; ns, not significant; sRVEF, systemic right ventricle ejection fraction; TR, tricuspid regurgitation.